+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID05010031

Phase 2 Study of Lower-Dose Radiation Therapy in Adults With Metastatic Cancer and ATM Gene Mutation

Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-05-11

45

Participants Needed

7

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying whether reduced-dose radiotherapy can effectively treat metastatic tumors that have a genetic change called an ATM mutation. The goal is to find the lowest radiation dose that still works to control these tumors. This phase II study is led by Memorial Sloan Kettering Cancer Center and focuses on precision radiation treatment for patients with these specific mutations. Participants will receive reduced doses of radiation targeted at progressive metastatic lesions seen on imaging, including bone metastases that may not cause symptoms. In the first stage, patients receive a dose of 4Gy twice, followed by evaluations at about 2 and 6 months. If successful, the second stage will explore further dose reductions with different palliative radiation schedules. The study design includes early stopping rules if treatment failure rates are too high compared to historical data. During the study, patients will undergo imaging to identify lesions to treat and will be monitored for treatment failure of the irradiated lesions up to 12 months. Researchers will check how well the tumors respond to the lower radiation doses and assess safety. The total follow-up and observation period will last at least a year to capture these outcomes and ensure patient well-being throughout the treatment period.

CONDITIONS

Brief Title

A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change

Research Team

A

Amy Xu, MD, PhD

D

Daniel Gomez, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here